F8 and hemophilia A: In conclusion, the administration of glycopegylated EHL FVIII at 50 IU/kg weekly or EHL FIX at 40 IU/kg every 21 days has demonstrated substantial improvements in bleeding outcomes, joint health, and functional independence in patients with hemophilia A and B. The significant reduction in ABR, coupled with enhanced QoL and adherence, underscores the potential of EHL therapies as a transformative approach to prophylactic treatment.